^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Halaven (eribulin mesylate)

    i
    Other names: E7389, ER-086526, B1939 mesylate, B-1939, Halichondrin B analog, NSC-707389
    Company:
    Eisai, Knight Therap, Shenzhen Kexing Pharma
    Drug class:
    Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor
    Related drugs:
    4d
    A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation (clinicaltrials.gov)
    P2, N=26, Not yet recruiting, Hu Hai
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    HER-2 amplification • HER-2 negative • PIK3CA mutation • HER-2 negative + HR negative
    |
    Halaven (eribulin mesylate) • Itovebi (inavolisib)
    4d
    Efficacy and safety of eribulin plus gemcitabine as second-line treatment for recurrent HER2-negative breast cancer: a phase II, single-arm, open-label trial. (PubMed, Commun Med (Lond))
    Eribulin plus gemcitabine is effective and well-tolerated in patients with HER2-negative metastatic breast cancer needing second-line or later treatment, providing a valuable treatment option.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    gemcitabine • Halaven (eribulin mesylate)
    7d
    Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease (clinicaltrials.gov)
    P2, N=90, Recruiting, Delcath Systems Inc. | Not yet recruiting --> Recruiting | Initiation date: Sep 2025 --> Jan 2026
    Enrollment open • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification • HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Melblez Kit (melphalan hepatic delivery system)
    8d
    Effects of Eribulin on Epithelial-Mesenchymal Plasticity in Patient-Derived Breast Cancer Cultures and Excised Tissues. (PubMed, Cancers (Basel))
    Our data highlight the presence of contextual parameters which govern the degree of EMT regulation by eribulin.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDH1 (Cadherin 1)
    |
    doxorubicin hydrochloride • Halaven (eribulin mesylate)
    9d
    BNT327-02: Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, BioNTech SE | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive
    |
    carboplatin • gemcitabine • paclitaxel • albumin-bound paclitaxel • Halaven (eribulin mesylate) • pumitamig (BNT327)
    10d
    BCTOP-T-M01: Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=134, Recruiting, Fudan University | N=192 --> 134 | Trial completion date: Feb 2026 --> Nov 2026 | Trial primary completion date: Aug 2025 --> May 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Avastin (bevacizumab) • carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate)
    17d
    AT148009: A Study of Evorpacept (ALX148) in Patients with Metastatic HER2-Positive Breast Cancer (2025-522012-16-00)
    P1/2, N=36, Not yet recruiting, Alx Oncology Holdings Inc.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • gemcitabine • paclitaxel • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • evorpacept (ALX148)
    17d
    PHP-MBC-202: Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients with Metastatic Breast Cancer (2025-521966-91-00)
    P1/2, N=12, Not yet recruiting, Delcath Systems Inc.
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 amplification • HER-2 negative
    |
    capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Melblez Kit (melphalan hepatic delivery system)
    21d
    OlympiAD: Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (clinicaltrials.gov)
    P3, N=302, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • capecitabine • Halaven (eribulin mesylate)
    22d
    A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative • EGFR expression • EGFR positive • EGFR negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • SYS6010
    24d
    EmpowHER-303: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer (clinicaltrials.gov)
    P3, N=550, Recruiting, Jazz Pharmaceuticals | Trial completion date: Nov 2031 --> Oct 2030 | Trial primary completion date: Sep 2028 --> Apr 2028
    Trial completion date • Trial primary completion date
    |
    HER-2 positive
    |
    gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Ziihera (zanidatamab-hrii)
    25d
    EVER-132-002: Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) (clinicaltrials.gov)
    P3, N=331, Active, not recruiting, Gilead Sciences | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    gemcitabine • capecitabine • Halaven (eribulin mesylate) • vinorelbine tartrate • Trodelvy (sacituzumab govitecan-hziy)